Trials / Terminated
TerminatedNCT03366675
AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]
Phase II, Single-arm Study of AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm, multi-center phase II study of AZD 2811 monotherapy in patients with relapsed small cell lung cancer (SCLC) as a second or third line therapy. Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2811 | AZD2811 100mg/vial |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2018-10-08
- Completion
- 2018-10-29
- First posted
- 2017-12-08
- Last updated
- 2018-11-27
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03366675. Inclusion in this directory is not an endorsement.